X
Healthians

₹0.00

mrf 0.00%
13 Nov 4:01 p.m.

Listing Status:

Connect: •••
•••• ••••
•••
Key Metrics of Healthians
  • Market Cap
  • Total Equity Funding ₹594 Cr in 11 rounds
  • Latest Funding Round ₹407 Cr, Series C Jan 03, 2022
  • Post Money Valuation ₹434 Cr as on Jan 31, 2023
  • Annual Revenue ₹361 Cr
    ▲ 34% YoYas on Mar 31, 2026
  • EBITDA ₹21 Cr
    ▼ 47% YoYas on Mar 31, 2026
  • EBITDA Margin 5.81%
    ▼ 61% YoYas on Mar 31, 2026
  • Net Profit ₹5.4 Cr
    ▲ 214% YoYas on Mar 31, 2026
  • Net Profit Margin 1.51%
    ▲ 185% YoYas on Mar 31, 2026
About the Company

Online platform for at-home diagnostic tests and health checkups. It offers full body checkups and blood tests with home sample...

Loading...
Price on BSE Volume

Funding Rounds

Total Rounds: 11 Healthians

S.No. Date Round Name Amount TTM Revenue Investors & Facilitators
1. Jan 3, 2022 Series C ₹407 Cr ₹153 Cr
Inst: WestBridge Capital, Trifecta Capital, Konark Trust, MMPL Trust
2. 2022 Grant (prize money) - ₹144 Cr
Inst: ACT Grants
3. Dec 16, 2021 Series B ₹61 Cr ₹144 Cr
Inst: Beenext, Mistletoe, Kotak Mahindra Bank, Ysinvestment, DG Ventures
4. Aug 21, 2019 Series B ₹85 Cr ₹37 Cr
Inst: DG Daiwa Ventures, Trifecta Capital, Tokio Marine, DGLabs, Beenos, M&S Partners, Beenext, DG Ventures, Kotak Investment Advisors, Tokio Marine, DG Incubation, Mistletoe, SIN Capital, Tokio Marine & Nichido Fire Insurance
Angel: Jean, Walter, Mamoru, Taniya
5. Dec 14, 2018 Series A ₹1.3 Cr ₹30 Cr
Inst: Trifecta Capital, Brand Capital
6. Feb 6, 2018 Conventional Debt ₹5.1 Cr ₹18 Cr
Inst: DGLabs
Angel: Walter T, Jean Pierrie, Mamoru
7. May 4, 2017 Series A ₹16 Cr ₹9.3 Cr
Inst: Beenext, Beenos, YouWeCan Ventures, M&S Capital Partners, MAFFIN, Ignis Inc, DG Ventures, Maffin
Angel: Yuvraj, Taniya, Jean, Walter T, Chigusa, Deepak
8. Oct 17, 2016 Series A ₹11 Cr ₹4.9 Cr
Inst: Beenext, Beenos, DG Ventures
Angel: Oleg
9. Nov 10, 2015 Seed ₹6.8 Cr ₹79.0 Lakh
Inst: Beenext, M&S Capital Partners, Dinco Overseas, DG Ventures
10. Aug 21, 2015 Seed ₹85.7 Lakh ₹49.5 Lakh
Inst: YouWeCan Ventures, Mconverge Ventures, Vnu Technologies
Angel: Aprameya, Subramanya
11. Sep 11, 2014 Angel ₹20.0 Lakh ₹22,353
Angel: Sharda, Chandan, Medha, Rajneesh, Anil, Sunil, Suhail, Pradeep

Financial Statements

Revenue - INR (Cr)

Net Profit/Loss - INR (Cr)

Select a year from the tabs

FY 25-26
FY 24-25
FY 23-24
FY 22-23
FY 21-22
FY 20-21
FY 19-20
FY 18-19
FY 17-18
FY 16-17
FY 15-16
FY 14-15
FY 13-14
Detailed Income StatementFY 25-26 (in Cr)
361.5
364.1
Total profit before exceptional items, extraordinary items and tax (2.7)
Exceptional items before tax 8.5
Total profit before tax 5.8
Total tax expense 0
Total profit (loss) for period from continuing operations 5.8
Profit (loss) from discontinuing operations before tax (0.4)
Tax expense of discontinuing operations 0
Total profit (loss) from discontinuing operation after tax (0.4)
Total profit (loss) for period 5.4
Basic earning per equity share 0.0
Detailed Balance SheetFY 25-26 (in Cr)
163.4
163.4
Detailed Cash Flow StatementFY 25-26 (in Cr)
Net cash from / (used in) operating activities (10.8)
Net cash from / (used in) investing activities (22.1)
Net cash from / (used) in financing activities 8.4
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes (24.4)
Net increase / (decrease) in cash and cash equivalents (24.4)
Cash and cash equivalents at the beginning of the year 29.1
Cash and cash equivalents at the end of the year 4.7
Detailed Income StatementFY 24-25 (in Cr)
270.5
275.2
Total profit before exceptional items, extraordinary items and tax (4.8)
Exceptional items before tax 0
Total profit before tax (4.8)
Total tax expense 0
Total profit (loss) for period from continuing operations (4.8)
Profit (loss) from discontinuing operations before tax 0
Tax expense of discontinuing operations 0
Total profit (loss) from discontinuing operation after tax 0
Total profit (loss) for period (4.8)
Basic earning per equity share (0.0)
Detailed Balance SheetFY 24-25 (in Cr)
224.2
224.2
Detailed Cash Flow StatementFY 24-25 (in Cr)
Net cash from / (used in) operating activities 9.3
Net cash from / (used in) investing activities 29.1
Net cash from / (used) in financing activities (19.1)
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes 19.4
Net increase / (decrease) in cash and cash equivalents 19.4
Cash and cash equivalents at the beginning of the year 9.7
Cash and cash equivalents at the end of the year 29.1
Detailed Income StatementFY 23-24 (in Cr)
252.7
297.7
Total profit before exceptional items, extraordinary items and tax (45.0)
Total profit before tax (45.0)
Total tax expense 0
Total profit (loss) for period from continuing operations (45.0)
Total profit (loss) for period (45.0)
Detailed Balance SheetFY 23-24 (in Cr)
220.6
220.6
Detailed Cash Flow StatementFY 23-24 (in Cr)
Net cash from / (used in) operating activities (41.0)
Net cash from / (used in) investing activities 77.3
Net cash from / (used) in financing activities (42.0)
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes (5.7)
Effect of exchange rate changes on cash and cash equivalents 0.0
Net increase / (decrease) in cash and cash equivalents (5.7)
Cash and cash equivalents at the beginning of the year 15.4
Cash and cash equivalents at the end of the year 9.7
Detailed Income StatementFY 22-23 (in Cr)
235.8
365.1
Total profit before exceptional items, extraordinary items and tax (129.3)
Total profit before tax (129.3)
0
Total profit (loss) for period from continuing operations (129.3)
Total profit (loss) for period (129.3)
Detailed Balance SheetFY 22-23 (in Cr)
301.9
301.9
Detailed Cash Flow StatementFY 22-23 (in Cr)
Net cash from / (used in) operating activities (143.7)
Net cash from / (used in) investing activities 86.8
Net cash from / (used) in financing activities (34.3)
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes (91.3)
Net increase / (decrease) in cash and cash equivalents (91.3)
Cash and cash equivalents at the beginning of the year 106.6
Cash and cash equivalents at the end of the year 15.4
Detailed Income StatementFY 21-22 (in Cr)
169.3
745.0
Total profit before exceptional items, extraordinary items and tax (575.8)
Total profit before tax (575.8)
Total tax expense 0
Total profit (loss) for period from continuing operations (575.8)
Total profit (loss) for period (575.8)
Detailed Balance SheetFY 21-22 (in Cr)
470.2
470.2
Detailed Cash Flow StatementFY 21-22 (in Cr)
Net cash from / (used in) operating activities (114.6)
Net cash from / (used in) investing activities (186.1)
Net cash from / (used) in financing activities 395.9
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes 95.3
Net increase / (decrease) in cash and cash equivalents 95.3
Cash and cash equivalents at the beginning of the year 11.4
Cash and cash equivalents at the end of the year 106.6
Detailed Income StatementFY 20-21 (in Cr)
68.7
113.2
Total profit before prior period items, exceptional items, extraordinary items and tax (44.5)
Total profit before extraordinary items and tax (44.5)
Total profit before tax (44.5)
0
Total profit (loss) for period from continuing operations (44.5)
Total profit (loss) for period before minority interest (44.5)
Total profit (loss) for period (44.5)
Basic earning per equity share 0
Diluted earnings per equity share 0
Detailed Balance SheetFY 20-21 (in Cr)
81.9
81.9
Detailed Cash Flow StatementFY 20-21 (in Cr)
Cash flow from operating activities (29.1)
Net cash from / (used in) operating activities (29.1)
Cash flow from investing activities (25.0)
Net cash from / (used in) investing activities (25.0)
Cash flow from financing activities 56.9
Net cash from / (used) in financing activities 56.9
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes 2.8
Net increase / (decrease) in cash and cash equivalents 2.8
Cash and cash equivalents at the beginning of the year 8.6
Cash and cash equivalents at the end of the year 11.4
Detailed Income StatementFY 19-20 (in Cr)
42.0
77.3
Total profit before prior period items, exceptional items, extraordinary items and tax (35.3)
Exceptional items before tax 0
Total profit before extraordinary items and tax (35.3)
Extraordinary items before tax 0
Total profit before tax (35.3)
0
Total profit (loss) for period from continuing operations (35.3)
Profit (loss) from discontinuing operations before tax 0
Tax expense of discontinuing operations 0
Total profit (loss) from discontinuing operation after tax 0
Total profit (loss) for period (35.3)
Basic earning per equity share before extraordinary items (0.0)
Diluted earnings per equity share before extraordinary items (0.0)
Basic earning per equity share (0.0)
Diluted earnings per equity share (0.0)
Detailed Balance SheetFY 19-20 (in Cr)
47.8
47.8
Detailed Cash Flow StatementFY 19-20 (in Cr)
Detailed Income StatementFY 18-19 (in Cr)
33.3
60.3
Total profit before prior period items, exceptional items, extraordinary items and tax (27.0)
Exceptional items before tax 0
Total profit before extraordinary items and tax (27.0)
Extraordinary items before tax 0
Total profit before tax (27.0)
0
Total profit (loss) for period from continuing operations (27.0)
Profit (loss) from discontinuing operations before tax 0
Tax expense of discontinuing operations 0
Total profit (loss) from discontinuing operation after tax 0
Total profit (loss) for period (27.0)
Basic earning per equity share before extraordinary items (0.0)
Diluted earnings per equity share before extraordinary items (0.0)
Basic earning per equity share (0.0)
Diluted earnings per equity share (0.0)
Detailed Balance SheetFY 18-19 (in Cr)
17.8
17.8
Detailed Cash Flow StatementFY 18-19 (in Cr)
Detailed Income StatementFY 17-18 (in Cr)
18.5
35.3
Total profit before prior period items, exceptional items, extraordinary items and tax (16.7)
Exceptional items before tax 0
Total profit before extraordinary items and tax (16.7)
Extraordinary items before tax 0
Total profit before tax (16.7)
(0.0)
Total profit (loss) for period from continuing operations (16.7)
Profit (loss) from discontinuing operations before tax 0
Tax expense of discontinuing operations 0
Total profit (loss) from discontinuing operation after tax 0
Total profit (loss) for period (16.7)
Basic earning per equity share before extraordinary items (0.0)
Diluted earnings per equity share before extraordinary items (0.0)
Basic earning per equity share (0.0)
Diluted earnings per equity share (0.0)
Detailed Balance SheetFY 17-18 (in Cr)
7.5
7.5
Detailed Cash Flow StatementFY 17-18 (in Cr)
Detailed Income StatementFY 16-17 (in Cr)
7.5
20.4
Total profit before prior period items, exceptional items, extraordinary items and tax (12.9)
Exceptional items before tax 0
Total profit before extraordinary items and tax (12.9)
Extraordinary items before tax 0
Total profit before tax (12.9)
0.0
Total profit (loss) for period from continuing operations (12.9)
Profit (loss) from discontinuing operations before tax 0
Tax expense of discontinuing operations 0
Total profit (loss) from discontinuing operation after tax 0
Total profit (loss) for period (12.9)
Basic earning per equity share before extraordinary items (0.0)
Diluted earnings per equity share before extraordinary items (0.0)
Basic earning per equity share (0.0)
Diluted earnings per equity share (0.0)
Detailed Balance SheetFY 16-17 (in Cr)
4.8
4.8
Detailed Cash Flow StatementFY 16-17 (in Cr)
Detailed Income StatementFY 15-16 (in Cr)
1.2
0
Total profit before prior period items, exceptional items, extraordinary items and tax 1.2
Exceptional items before tax 0
Total profit before extraordinary items and tax 1.2
Extraordinary items before tax 0
Total profit before tax 1.2
0
Total profit (loss) for period from continuing operations 1.2
Profit (loss) from discontinuing operations before tax 0
Tax expense of discontinuing operations 0
Total profit (loss) from discontinuing operation after tax 0
Total profit (loss) for period 1.2
Basic earning per equity share before extraordinary items (0.0)
Diluted earnings per equity share before extraordinary items (0.0)
Basic earning per equity share (0.0)
Diluted earnings per equity share (0.0)
Detailed Balance SheetFY 15-16 (in Cr)
4.9
4.9
Detailed Cash Flow StatementFY 15-16 (in Cr)
Detailed Income StatementFY 14-15 (in Cr)
0.0
0.3
Total profit before prior period items, exceptional items, extraordinary items and tax (0.3)
Exceptional items before tax 0
Total profit before extraordinary items and tax (0.3)
Extraordinary items before tax 0
Total profit before tax (0.3)
0
Total profit (loss) for period from continuing operations (0.3)
Profit (loss) from discontinuing operations before tax 0
Tax expense of discontinuing operations 0
Total profit (loss) from discontinuing operation after tax 0
Total profit (loss) for period (0.3)
Basic earning per equity share before extraordinary items (0.0)
Diluted earnings per equity share before extraordinary items (0.0)
Basic earning per equity share (0.0)
Diluted earnings per equity share (0.0)
Detailed Balance SheetFY 14-15 (in Cr)
0.2
0.2
Detailed Cash Flow StatementFY 14-15 (in Cr)
Detailed Income StatementFY 13-14 (in Cr)
0
0.0
Profit/(Loss) before tax (0.0)
0
Profit/(Loss) for the year (0.0)
Detailed Balance SheetFY 13-14 (in Cr)
0.0
0.0
Detailed Cash Flow StatementFY 13-14 (in Cr)
Cash flow from operating activities 0
Net cash from/(used in) operating activities 0
Cash flow from investing activities 0
Net cash from/(used in) investing activities 0
Cash flow from financing activities 0
Net cash from/(used) in financing activities 0
Net increase/(decrease) in cash and cash equivalents before effect of exchange rate changes 0
Effect of exchange rate changes on cash and cash equivalents 0
Net increase /(decrease) in cash and cash equivalents 0
Cash and cash equivalents at the beginning of the year 0
Cash and cash equivalents at the end of the year 0

Shareholding Pattern

As of Mar 30, 2026 • Healthians

Total Shares 1.15M

Top Shareholders

Shareholder Category Shares (Mn) % Holding
WestBridge AIF - I Fund 0.28M 24.26%
Renu Sahni Other People 0.13M 11.36%
DG Resona Ventures No. 1 Investment Limited Fund 0.09M 7.54%
Deepak Sahni Founder 0.08M 6.95%
Beenext Accelerate Fund Fund 0.07M 5.83%
Others

    Top Competitors

    Similar companies to Healthians

    Airmed

    airmedlabs.com

    MAX Lab

    maxlab.co.in

    Curelo

    curelohealth.com

    Fastest Health

    fastest.health

    5th Vital

    5thvital.com

    Flebo.in

    flebo.in

    Latest News

    Updates on Healthians
    Need help? Chat with us! WhatsApp